Welcome to our dedicated page for Apyx Medical Corporation news (Ticker: APYX), a resource for investors and traders seeking the latest updates and insights on Apyx Medical Corporation stock.
Apyx Medical Corporation (NASDAQ: APYX) is a surgical aesthetics and advanced energy technology company whose news flow centers on its Helium Plasma Platform Technology products, including Renuvion, the AYON Body Contouring System, and J-Plasma. Company press releases focus on developments in the cosmetic surgery market, the hospital surgical market, and OEM relationships with other medical device manufacturers.
Investors and observers following APYX news will see regular updates on financial performance, such as quarterly and annual revenue results, preliminary unaudited revenue ranges, and segment-level trends in Surgical Aesthetics and OEM revenue. The company also issues guidance updates and discusses factors influencing its revenue mix, including the commercial rollout of AYON and demand for single-use handpieces and generators.
Another key category of Apyx Medical news involves product and regulatory milestones. Recent announcements describe FDA 510(k) clearances and submissions related to the AYON Body Contouring System, as well as international regulatory approvals like the Ministry of Food and Drug Safety clearance in South Korea for the Apyx One console and single-use handpieces. These items highlight how the company is expanding the indications and geographic reach of its platforms.
APYX news also covers capital markets and corporate actions, including proposed and completed public offerings of common stock under an effective Form S-3 shelf registration statement, as reported in 8-K filings and related press releases. Additional items include notices of investor conference participation, inducement equity awards under Nasdaq Listing Rule 5635(c)(4), and information about annual stockholder meetings and governance matters.
This news page aggregates these disclosures so readers can review Apyx Medical’s earnings releases, product launch updates, regulatory submissions, financing transactions, and investor events in one place.
Apyx Medical (NASDAQ:APYX) announced that President and CEO Charles Goodwin and CFO Matt Hill will attend investor meetings in New York in November 2025.
They will participate in 1x1 meetings at the 16th Annual Craig-Hallum Alpha Select Conference on November 18, 2025 at Sheraton NY Times Square, and at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 20, 2025 at Westin NY Grand Central.
Investors seeking meetings should contact their Craig Hallum or Canaccord Genuity representatives. The release also restates the company’s Helium Plasma Platform products (Renuvion, AYON Body Contouring System, J-Plasma), notes >90 clinical documents supporting Renuvion and J-Plasma, and describes AYON as FDA-cleared.
Apyx Medical (NASDAQ: APYX) announced it will release its third quarter fiscal 2025 financial results before markets open on Thursday, November 6, 2025.
Management will host a conference call at 8:00 a.m. Eastern Time on November 6 to discuss results and conduct a Q&A. Dial-in numbers are 800-717-1738 (U.S.) or 646-307-1865 (international) with access code 73607. A live webcast will be available and archived in the company’s Investor Relations section.
Contact for investors is Jeremy Feffer at LifeSci Advisors (212-915-2568; jfeffer@lifesciadvisors.com). The company sells helium plasma and RF products under the Renuvion, AYON Body Contouring System, and J-Plasma brands, supported by more than 90 clinical publications.
Apyx Medical (NASDAQ: APYX) announced on October 13, 2025 that it submitted a new FDA 510(k) premarket notification to expand the label of the AYON Body Contouring System to include power liposuction.
The company began a nationwide commercial launch of AYON in September 2025 and said that, if cleared, the power liposuction function could be activated in systems already installed at U.S. surgical centers.
A virtual key opinion leader event on October 14, 2025 will discuss the commercial launch.
Apyx Medical (NASDAQ:APYX) announced a virtual Key Opinion Leader (KOL) event scheduled for October 14, 2025, at 12:00 PM ET. The event will feature Dr. Paul Vanek, Jr., FACS, alongside company management, to discuss the commercial launch of the AYON Body Contouring System™.
The AYON system is the first FDA-cleared all-in-one platform for aesthetic surgical suites, incorporating the company's proprietary Renuvion technology. The system combines fat removal, closed loop contouring, tissue contraction, and electrosurgical capabilities, designed to streamline procedures and enhance patient outcomes. The event will include formal presentations followed by a Q&A session.
Apyx Medical Corporation (NASDAQ:APYX) has granted a nonstatutory stock option to John Featherstone, the company's Vice President of North American Sales, as part of his employment inducement. The stock option allows for the purchase of 100,000 shares of common stock at an exercise price of $1.85 per share, based on the closing price on August 4, 2025.
The stock option features a four-year vesting schedule, with 25% of shares vesting on the first anniversary and the remainder vesting annually thereafter, contingent upon continued employment. Apyx Medical specializes in advanced energy technology, particularly its Helium Plasma Platform Technology, marketed as Renuvion® and AYON Body Contouring System™ for cosmetic surgery, and J-Plasma® for hospital surgical applications.
Apyx Medical Corporation (NASDAQ:APYX), a leader in advanced energy technology and manufacturer of Renuvion® and AYON Body Contouring System™, has announced two key executive appointments to strengthen its global sales leadership. John Featherstone joins as Vice President of North American Sales, bringing over 20 years of aesthetics and medical device industry experience. Simon Davies has been appointed as Director of International Sales for Europe and Asia-Pacific, contributing 30 years of global sales leadership expertise.
These strategic hires are aimed at supporting the commercial launch of AYON, the industry's first all-in-one surgical body contouring system, and accelerating the company's global expansion efforts. The appointments align with Apyx's commitment to scaling its commercial operations and enhancing market penetration across key regions.
Apyx Medical (NASDAQ:APYX) reported Q2 2025 financial results with total revenue of $11.4 million, down from $12.1 million year-over-year. The company highlighted the successful launch of its AYON Body Contouring System™ and initiated Renuvion® sales in China.
Key financials include a reduced net loss of $3.8 million (down 42% YoY) and an Adjusted EBITDA loss of $2.0 million (improved 54% YoY). Following strong AYON pre-sales, Apyx increased its FY2025 revenue guidance to $50.0-52.0 million, up from previous guidance of $47.6-49.0 million.
Advanced Energy segment revenue remained relatively flat at $9.7 million, while OEM revenue decreased 28.5% to $1.7 million. The company plans a full commercial launch of AYON in September 2025.
Apyx Medical Corporation (NASDAQ:APYX), a leader in advanced energy technology, announced its participation in the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025, in Boston, MA.
CEO Charlie Goodwin and CFO Matt Hill will conduct a fireside chat at 4:00pm ET and hold one-on-one investor meetings throughout the day. The presentation will be available via live webcast with a replay option on the company's investor relations website.
Apyx Medical specializes in Helium Plasma Platform Technology, marketing Renuvion® and AYON Body Contouring System™ for cosmetic surgery and J-Plasma® for hospital surgical markets, with efficacy supported by over 90 clinical publications.
[]Apyx Medical Corporation (NASDAQ:APYX) has announced the launch of its Renuvion® technology in China, marking a significant expansion into one of the world's largest healthcare markets. The company has entered into a distribution agreement with GlamMoon Medical Technology, a division of BeauCare Clinics Investment Co., Ltd. (BCC), following initial market clearance from China's National Medical Products Administration.
The partnership with BCC, which operates over 60 medical aesthetics hospitals and clinics across 15 Chinese cities, positions Renuvion for significant market penetration. Early clinical interest and completed procedures indicate strong market potential for Apyx's helium plasma technology, which is supported by more than 90 clinical documents.
Apyx Medical Corporation (NASDAQ:APYX), a manufacturer of advanced helium plasma and radiofrequency technology, will release its Q2 2025 financial results on August 7, 2025, after market close. The company will host a conference call at 4:30 PM ET the same day.
Apyx Medical specializes in the Renuvion® and AYON Body Contouring System™ for the cosmetic surgery market, and J-Plasma® for hospital surgical applications. Their technology's effectiveness is backed by over 90 clinical publications, demonstrating their strong presence in the advanced energy technology sector.